RecruitingNCT05214612

Predictors and Prognostic Factors of Myasthenia Gravis Outcome

Sponsor

Assiut University

Enrollment

30 participants

Start Date

Jan 1, 2022

Study Type

OBSERVATIONAL

Conditions

Myasthenia Gravis Thymoma Nervous System Diseases Autoimmune Diseases of the Nervous System Myasthenia Gravis, Generalized Myasthenia Gravis Crisis Myasthenia Gravis with Exacerbation (Disorder)Myasthenia Gravis, Adult Form Myasthenia Gravis, Ocular Neuromuscular Junction Diseases Thymus Hyperplasia Myasthenia Gravis, Juvenile Form

Summary

This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG. The predictors are including primary outcome (percentage of changes in MG scales at baseline at time of enrollment and after 3 months) and secondary outcome (treatment-related adverse events). Also it aims to determine the frequency of patients with refractory MG. This information will be used to understand the trends and mechanisms of disease relapse, and optimal management strategies.

Eligibility

Min Age: 16 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Drug treatment of myasthenia gravis and treatment of crisis for people with autoimmune diseases of the nervous system, myasthenia gravis, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTDrug treatment of myasthenia gravis and treatment of crisis

Patients with myasthenia gravis who are receiving medical treatment and treatment of crisis as plasmapheresis

Locations(1)

Assiut University

Asyut, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05214612

Related Trials

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT0622020135 locations

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

NCT0750170224 locations

PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis

NCT077172811 location

A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

NCT076737442 locations

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

NCT019505721 location